5l72: Difference between revisions

Line 1:

~~'''Unreleased structure'''~~

~~The entry~~ 5l72 is ~~ON HOLD~~

==PI3 kinase delta in complex with N-[6-(5-methanesulfonamido-6-methoxypyridin-3-yl)-1,3-dihydro-2-benzofuran-4-yl]-2-(morpholin-4-yl)acetamide==

== Structural highlights ==

<table><tr><td colspan='2'>[[5l72]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5L72 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5L72 FirstGlance]. <br>

</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6PF:N-[6-(5-METHANESULFONAMIDO-6-METHOXYPYRIDIN-3-YL)-1,3-DIHYDRO-2-BENZOFURAN-4-YL]-2-(MORPHOLIN-4-YL)ACETAMIDE'>6PF</scene></td></tr>

<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5l72 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5l72 OCA], [http://pdbe.org/5l72 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5l72 RCSB], [http://www.ebi.ac.uk/pdbsum/5l72 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5l72 ProSAT]</span></td></tr>

</table>

== Publication Abstract from PubMed ==

A four step process of high quality modelling of existing data, deconstruction, identification of replacement cores and an innovative synthetic re-growth strategy led to the rapid discovery of a novel oral series of PI3K delta inhibitors with promising selectivity and excellent in vivo characteristics.

~~Authors~~:

Evolution of a novel orally bioavailable series of PI3K delta inhibitors from an inhaled lead for the treatment of respiratory disease.,Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Perez D, Peace S, Rowland P, Tame C, Uddin S, Vitulli G, Wellaway N J Med Chem. 2016 Jul 18. PMID:27429068<ref>PMID:27429068</ref>

~~Description~~:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>

[[Category: ~~Unreleased Structures~~]]

</div>

== References ==

__TOC__

</StructureSection>

[[Category: Rowland, P]]

[[Category: Pi3 kinase delta]]

[[Category: Transferase]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 5l72 is ON HOLD
+==PI3 kinase delta in complex with N-[6-(5-methanesulfonamido-6-methoxypyridin-3-yl)-1,3-dihydro-2-benzofuran-4-yl]-2-(morpholin-4-yl)acetamide==
+<StructureSection load='5l72' size='340' side='right' caption='[[5l72]], [[Resolution|resolution]] 3.06&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[5l72]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5L72 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5L72 FirstGlance]. <br>
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6PF:N-[6-(5-METHANESULFONAMIDO-6-METHOXYPYRIDIN-3-YL)-1,3-DIHYDRO-2-BENZOFURAN-4-YL]-2-(MORPHOLIN-4-YL)ACETAMIDE'>6PF</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5l72 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5l72 OCA], [http://pdbe.org/5l72 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5l72 RCSB], [http://www.ebi.ac.uk/pdbsum/5l72 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5l72 ProSAT]</span></td></tr>
+</table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+A four step process of high quality modelling of existing data, deconstruction, identification of replacement cores and an innovative synthetic re-growth strategy led to the rapid discovery of a novel oral series of PI3K delta inhibitors with promising selectivity and excellent in vivo characteristics.
-Authors:
+Evolution of a novel orally bioavailable series of PI3K delta inhibitors from an inhaled lead for the treatment of respiratory disease.,Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Perez D, Peace S, Rowland P, Tame C, Uddin S, Vitulli G, Wellaway N J Med Chem. 2016 Jul 18. PMID:27429068<ref>PMID:27429068</ref>
-Description:
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
+<div class="pdbe-citations 5l72" style="background-color:#fffaf0;"></div>
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Rowland, P]]
+[[Category: Pi3 kinase delta]]
+[[Category: Transferase]]